What Are Low-Dose RAAS Inhibitors?
Low-dose RAAS inhibitors refer to submaximal doses of ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists that are below the guideline-recommended target doses proven to reduce cardiovascular and renal events in clinical trials. These reduced doses are commonly used in clinical practice, though they are associated with worse outcomes compared to target dosing 1.
Clinical Context and Prevalence
In real-world practice, the majority of patients receive low-dose RAAS inhibitors rather than optimal therapy:
- Only 19-30% of patients achieve guideline-recommended target doses of ACE inhibitors, ARBs, or MRAs 1
- 58-65% of patients remain on submaximal doses 1
- In the ESC Heart Failure Long-Term Registry, less than one-third of HFrEF patients were on target doses (29.3% for ACEi, 24.1% for ARB, 30.5% for MRA) 1
Why Low Doses Are Used (Common Reasons)
The primary drivers forcing clinicians to use low doses include:
- Hyperkalaemia (K+ >5.0 mEq/L) - the most common reason, accounting for non-use in 8.5% of ACEi/ARB patients and 35.1% of MRA patients 1
- Symptomatic hypotension 1, 2
- Worsening renal function 1
- Inadequate monitoring - K+ levels are frequently under-monitored despite guideline recommendations 1
Notably, in about one-third of patients not achieving target doses, no clear reason was documented 1, suggesting suboptimal clinical practice.
Clinical Consequences of Low-Dose Therapy
The use of low-dose RAAS inhibitors is associated with significantly worse outcomes:
- Patients achieving <50% of recommended ACEi/ARB doses had increased risk of death and/or HF hospitalization compared to those reaching ≥100% of target dose 1
- Among CKD patients on submaximal doses: 24.9% experienced cardio-renal adverse events/mortality and 8.2% died 1
- In contrast, patients on maximum doses had only 4.1% mortality 1
- Discontinuation of RAAS inhibitors resulted in even worse outcomes: 34.3% cardio-renal events and 11.0% mortality 1
Guideline-Recommended Approach
RAAS therapy should be started at low dosage initially, then titrated to maximum tolerated evidence-based doses 1:
- Start an ACEi (or ARB when indicated) first at low dose
- Add an MRA thereafter
- Titrate to maximum tolerated doses shown to reduce cardiovascular and renal events in trials
Management Algorithm Based on Potassium Levels:
- K+ 4.5-5.0 mEq/L not on target dose: Titrate/start RAAS inhibitors and closely monitor K+ 1
- K+ >5.0 mEq/L on maximum tolerated dose: Initiate K+ lowering agents (patiromer, sodium zirconium cyclosilicate) 1
- K+ >5.0 mEq/L not on target dose: Initiate K+ lowering agents, then titrate RAAS inhibitors when K+ <5.0 mEq/L 1
- K+ >5.5 mEq/L: Reduce dose or stop ACEi/ARB 1
- K+ >6.0 mEq/L: Stop RAAS inhibitors 1
Critical Pitfall to Avoid
The poor outcomes associated with RAAS inhibitor side effects may stem from discontinuing or under-dosing the therapy rather than the side effects themselves 2. When hyperkalaemia occurs, it may serve as a risk marker contributing to therapy discontinuation and suboptimal use, ultimately resulting in higher mortality rates 2.
In acute HF settings with low blood pressure, consider initiating very low-dose ARNI (25 mg twice daily) and up-titrating, or shifting to low-dose ACEi/ARB if not tolerated 2. During dose adjustments, prioritize continuing SGLT2 inhibitors and MRAs when possible, as these have the least impact on blood pressure 2.
The availability of newer potassium binders (patiromer, sodium zirconium cyclosilicate) now enables maintenance of optimal RAAS inhibitor dosing despite hyperkalaemia 1.